ContraVir Pharmaceuticals to Present at BIO-Europe Spring 2017
March 14 2017 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today that it will present
at BIO-Europe Spring 2017 to be held March 20-22, 2017, in
Barcelona, Spain.
James Sapirstein, Chief Executive Officer of ContraVir, will
provide an overview of the Company's business during his live
presentation and will be available to participate in one-on-one
meetings with investors who are registered to attend the
conference.
Event: BIO-Europe Spring
2017Date: Wednesday, March 22,
2017Time: 10:00AM (Central European
Time)Presentation Room: 118 on level
1Location: Barcelona, Spain
About ContraVir Pharmaceuticals ContraVir is a
biopharmaceutical company focused on the development and
commercialization of targeted antiviral therapies with a specific
focus on developing a potentially curative therapy for hepatitis B
virus (HBV). The Company is developing two novel anti-HBV compounds
with complementary mechanisms of action: Tenofovir Exalidex (TXL™,
formerly CMX157), a highly potent analog of the successful
antiviral drug tenofovir currently in Phase 2a, which has
demonstrated the potential for low, once a day dosing compared to
Viread® and decreased systemic exposure, thereby potentially
reducing renal and bone side effects; and CRV431, a next generation
cyclophilin inhibitor with a unique structure that increases its
potency and selective index against HBV. ContraVir is also
developing Valnivudine™ (formerly FV-100), an orally available
nucleoside analogue prodrug for the treatment of herpes zoster, or
shingles, in a Phase 3 clinical trial. In addition to direct
antiviral activity, Valnivudine™ has demonstrated the potential to
reduce the incidence of debilitating shingles-associated pain known
as post-herpetic neuralgia (PHN) in a Phase 2 clinical
study. For more information visit www.contravir.com.
Forward Looking Statements Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend,"
among others. These forward-looking statements are based on
ContraVir's current expectations and actual results could differ
materially. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir does
not undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth in
ContraVir's Form 10-K for the year ended June 30, 2016, and other
periodic reports filed with the Securities and Exchange
Commission.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Apr 2023 to Apr 2024